QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.12%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:ARGX

argenx (ARGX) Stock Forecast, Price & News

$483.54
-25.24 (-4.96%)
(As of 09/26/2023 ET)
Compare
Today's Range
$473.53
▼
$488.59
50-Day Range
$483.54
▼
$548.43
52-Week Range
$333.07
▼
$550.76
Volume
639,088 shs
Average Volume
250,324 shs
Market Capitalization
$28.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$519.55
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

argenx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.76 Rating Score
Upside/​Downside
7.4% Upside
$519.55 Price Target
Short Interest
Healthy
1.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of argenx in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.10) to ($3.03) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

811th out of 964 stocks

Biological Products, Except Diagnostic Industry

130th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

ARGX stock logo

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Price History

ARGX Stock News Headlines

September 25, 2023 | marketbeat.com
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
September 21, 2023 | nasdaq.com
Argenx's Vyvgart Authorized For Sale In Canada For Generalized Myasthenia Gravis
September 26, 2023 | Micro-Cap Stock Trader (Ad)
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
September 21, 2023 | finance.yahoo.com
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 19, 2023 | americanbankingnews.com
argenx's (ARGX) Buy Rating Reiterated at HC Wainwright
September 15, 2023 | msn.com
How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug
September 15, 2023 | markets.businessinsider.com
Argenx: CHMP Recommends EC Approval For Subcutaneous Efgartigimod For Generalized Myasthenia Gravis
September 15, 2023 | finance.yahoo.com
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 31, 2023 | markets.businessinsider.com
What 20 Analyst Ratings Have To Say About argenx
August 30, 2023 | benzinga.com
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
August 22, 2023 | thestreet.com
argenx SE
August 21, 2023 | finance.yahoo.com
Should You Consider Adding argenx SE (ARGX) to Your Portfolio?
August 11, 2023 | benzinga.com
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
August 8, 2023 | finance.yahoo.com
Is Argenx Stock a Buy Now?
August 4, 2023 | seekingalpha.com
argenx: Three Important Milestones Reached In 2023, More To Come
August 1, 2023 | msn.com
Argen X SE - ADR (ARGX) Price Target Increased by 16.79% to 551.80
August 1, 2023 | markets.businessinsider.com
Stifel Nicolaus Reaffirms Their Buy Rating on Argenx Se (ARGX)
August 1, 2023 | benzinga.com
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
July 29, 2023 | msn.com
Argenx Beats Q2 Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%
July 28, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST), Argenx Se (ARGX) and HCA Healthcare (HCA)
July 28, 2023 | msn.com
Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%
July 27, 2023 | seekingalpha.com
argenx SE 2023 Q2 - Results - Earnings Call Presentation
July 27, 2023 | finanznachrichten.de
argenx SE: argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023 | benzinga.com
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023 | msn.com
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
July 25, 2023 | finanznachrichten.de
argenx SE: argenx announces closing of global offering
See More Headlines
Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings
7/27/2023
Today
9/26/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARGX
CUSIP
N/A
CIK
1697862
Web
www.argenx.com
Phone
(176) 303-0488
Fax
N/A
Employees
843
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$519.55
High Stock Price Forecast
$609.00
Low Stock Price Forecast
$246.00
Forecasted Upside/Downside
+7.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.76
Research Coverage
21 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($7.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-709,590,000.00
Net Margins
-47.28%
Pretax Margin
-52.69%
Return on Equity
-27.99%
Return on Assets
-25.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.47
Quick Ratio
7.84

Sales & Book Value

Annual Sales
$445.27 million
Price / Sales
63.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$50.79 per share
Price / Book
9.55

Miscellaneous

Outstanding Shares
58,540,000
Free Float
57,115,000
Market Cap
$28.40 billion
Optionable
Optionable
Beta
0.75
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Timothy Van Hauwermeiren EMBA (Age 51)
    M.B.A., M.Sc., MSc, CEO & Exec. Director
    Comp: $1.44M
  • Mr. Karl Gubitz (Age 53)
    Chief Financial Officer
  • Ms. Malini Moorthy (Age 53)
    Gen. Counsel
  • Mr. Arjen Lemmen M.Sc. (Age 38)
    VP of Corp. Devel. & Strategy
  • Ms. Andria Wilk (Age 49)
    Global Head of Quality
  • Mr. Luc Truyen (Age 58)
    Chief Medical Officer
  • Ms. Karen Massey (Age 44)
    Chief Operating Officer
  • Mr. Filip Borgions
    VP & Global Head of Technical Operations
  • Mr. Peter Ulrichts (Age 43)
    Chief Scientific Officer
  • Ms. Beth DelGiacco
    VP and Global Head of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.

What is argenx's stock price forecast for 2023?

21 brokerages have issued 1 year target prices for argenx's stock. Their ARGX share price forecasts range from $246.00 to $609.00. On average, they expect the company's share price to reach $519.55 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.

How have ARGX shares performed in 2023?

argenx's stock was trading at $378.83 at the beginning of the year. Since then, ARGX shares have increased by 28.1% and is now trading at $485.11.
View the best growth stocks for 2023 here.

When is argenx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ARGX earnings forecast.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Thursday, July, 27th. The company reported ($1.69) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.69). The firm earned $281.16 million during the quarter, compared to analysts' expectations of $258.32 million. argenx had a negative trailing twelve-month return on equity of 27.99% and a negative net margin of 47.28%. During the same period last year, the firm posted ($3.81) EPS.

What ETFs hold argenx's stock?

ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), Fidelity Disruptive Medicine ETF (FMED), First Trust NYSE Arca Biotechnology Index Fund (FBT), BlackRock Future Health ETF (BMED), AdvisorShares Dorsey Wright ADR ETF (AADR), Simplify Health Care ETF (PINK), iShares Biotechnology ETF (IBB) and American CenturyFocused Dynamic Growth ETF (FDG).

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.19%), Capital World Investors (2.02%), Jennison Associates LLC (1.98%), Bellevue Group AG (1.58%), BlackRock Inc. (1.01%) and Eventide Asset Management LLC (0.56%).

How do I buy shares of argenx?

Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $485.11.

How much money does argenx make?

argenx (NASDAQ:ARGX) has a market capitalization of $28.40 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($7.17) on an earnings per share basis.

How many employees does argenx have?

The company employs 843 workers across the globe.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -